Alt desc U.S. Department of Health & Human Services Alt descAlt desc National Institutes of Health Alt desc
Skip Over Navigation Links
Therapeutics for Rare and Neglected Diseases

Financial Success

An analysis finds that two NCATS rare diseases programs have led to reduced costs for developing new drugs and reduced financial risks.

Work with Us

The TRND program is designed to encourage and speed the development of new treatments for diseases with high unmet medical needs. Find project details, scientific capabilities, information for applicants and more.

Contact TRND

Therapeutics for Rare and Neglected Diseases (TRND)

The TRND program supports pre-clinical development of therapeutic candidates intended to treat rare or neglected disorders, with the goal of enabling an Investigational New Drug (IND) application. Learn more.

Find NCATS Programs & InitiativesAccess NCATS Expertise & Resources

About TRND

TRND supports pre-clinical development from lead optimization through IND application.

Scientific Capabilities

TRND offers world-class in-house experts and connections to external resources.

TRND Projects

Explore active and completed therapeutic development projects supported by TRND, including projects with clinical activities.

Why TRND Matters

There are more than 6,500 identified rare and neglected diseases, yet only about 250 treatments are available for these conditions. One reason is that limited numbers of patients can make gathering information and designing drug studies difficult. As a result, scientists often know little about the symptoms and biology of these conditions. Another obstacle is that some private companies may find it difficult to justify the cost of developing drugs for such small rare disease markets. Even in the case of infectious diseases — such as malaria — that inflict health burdens on large numbers of people in the developing world, the private sector often neglects therapeutic development because of insufficient economic incentives. Learn more about TRND.